Download PDF

Other users also viewed these articles

Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease Shan Hong; Yiwei Hao; Lei Sun; Ping Li; Junru Yang; Fuyang Zhang; Lingling He; Jing Zhang; Hongshan Wei;
10.1016/j.aohep.2024.101589
Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019 Jacob Romano; Jessica Burnside; Giada Sebastiani; Alnoor Ramji; Keyur Patel; Mark Swain; Sahar Saeed;
10.1016/j.aohep.2024.101757
FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease Mário Reis Álvares-da-Silva; Márcia da Silva Vargas; Soheyla Mohd Souza Rabie; Gabriella Jonko; Patricia Gabriela Riedel; Larisse Longo; Marcelo Rodrigues Gonçalves; Vivian Cristine Luft; Dvora Joveleviths;
10.1016/j.aohep.2024.101584